CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Filing of New Patent Application with USPTO

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced that it has filed a new patent application with the U.S. Patent and Trademark Office (“USPTO”) covering the use of its DehydraTECH™ technology for the delivery of phosphodiesterase type 5 (PDE5) inhibitors. Existing products occupying this space include Viagra™ (sildenafil) and Cialis™ (tadalafil). Per the update, a common complaint regarding existing PDE5 inhibitors relates to the slow-acting nature of the substances. Lexaria believes that its patented DehydraTECH™ technology, building on existing research with cannabinoid delivery, will allow for faster-acting treatments in many cases utilizing lower dosage quantities. Separately, Lexaria this morning announced that a number of existing stock options and warrants have been exercised, with the company receiving a total of $69,736.50 from the transaction.

To view the full press release, visit http://cnw.fm/3NYKe

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply